These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 24978857

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.
    Vaccine; 2015 Jan 01; 33(1):174-81. PubMed ID: 25444803
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.
    J Infect Dev Ctries; 2014 Sep 12; 8(9):1160-8. PubMed ID: 25212080
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.
    Vaccine; 2012 Jul 06; 30(32):4820-7. PubMed ID: 22626675
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.
    Pediatr Infect Dis J; 2012 Aug 06; 31(8):848-58. PubMed ID: 22801094
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Clin Vaccine Immunol; 2011 Aug 06; 18(8):1358-64. PubMed ID: 21715575
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
    Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R.
    Hum Vaccin Immunother; 2014 Aug 06; 10(1):92-9. PubMed ID: 24047817
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
    Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.
    Biologicals; 2012 Mar 06; 40(2):134-9. PubMed ID: 22261282
    [Abstract] [Full Text] [Related]

  • 20. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
    Chanthavanich P, Anderson E, Kerdpanich P, Bulitta M, Kanesa-Thasan N, Hohenboken M.
    Pediatr Infect Dis J; 2019 Jul 06; 38(7):757-764. PubMed ID: 31194712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.